nach oben

Annals of Hematology

Erschienen in:

21.01.2023 | Original Article

Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab

verfasst von: Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu

Erschienen in: Annals of Hematology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and the prognosis of the disease varied. This research aims to investigate the impact of serum lipid level on the outcome of DLBCL patients and their interaction with rituximab (RTX). Data of newly diagnosed DLBCL in the third affiliated hospital of Soochow University were retrospectively collected. Baseline serum lipid levels, clinical data, and survival information were simultaneously recorded. Data of healthy controls were collected with age matching. Serum lipid levels significantly differed for the patients. All were transformed into categorical variables for the analysis of survival. During a median follow-up of 58 months, 32.8% patients died. Univariate analysis revealed all serum lipid indicators were associated with overall survival (OS); all except for total cholesterol (TC) and apolipoprotein B (apoB) showed significant impact on progression-free survival (PFS). Multivariable analysis confirmed the adverse effect of triglyceride (TG) on PFS (P = 0.013) and favorable impact of high-density lipoprotein (HDL) on OS (P = 0.003). For cases treated without RTX, apolipoprotein A (apoA) had independent favorable effect on both PFS (P = 0.004) and OS (P = 0.001). Comparably, for patients who received RTX, HDL showed remarkably predictive value of PFS (P = 0.011) and OS (P = 0.019). In conclusion, the abnormal serum lipids occurred throughout the course of DLBCL, and the associations of serum lipids and the prognosis of the disease were interfered by RTX. Trial registration: 2022(科)CL033; June 26, 2022, retrospectively registered

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363–385. https://doi.org/10.3322/caac.21565CrossRef

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRef

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12):2040–2045. https://doi.org/10.1182/blood-2010-03-276246CrossRef

Harris LJ, Patel K, Martin M (2020) Novel therapies for relapsed or refractory diffuse large B-cell lymphoma. Int J Mol Sci 21(22):8553. https://doi.org/10.3390/ijms21228553CrossRef

Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol 182(5):633–643. https://doi.org/10.1111/bjh.15412CrossRef

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808. https://doi.org/10.1182/blood-2017-03-769620CrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70. https://doi.org/10.1016/s0092-8674(00)81683-9CrossRef

Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314. https://doi.org/10.1126/science.123.3191.309CrossRef

Baenke F, Peck B, Miess H, Schulze A (2013) Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 6(6):1353–1363. https://doi.org/10.1242/dmm.011338CrossRef

10.

Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16(3):202–208. https://doi.org/10.1016/s0899-9007(99)00266-xCrossRef

11.

Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763–777. https://doi.org/10.1038/nrc2222CrossRef

12.

Maier T, Jenni S, Ban N (2006) Architecture of mammalian fatty acid synthase at 4.5 A resolution. Science 311(5765):1258–1262. https://doi.org/10.1126/science.1123248CrossRef

13.

Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66(12):5977–5980. https://doi.org/10.1158/0008-5472.CAN-05-4673CrossRef

14.

Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28(6):686–692. https://doi.org/10.1016/s0046-8177(97)90177-5CrossRef

15.

Sebastiani V, Visca P, Botti C, Santeusanio G, Galati GM, Piccini V, Capezzone de Joannon B, Di Tondo U, Alo PL (2004) Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol 92(1):101–105. https://doi.org/10.1016/j.ygyno.2003.10.027CrossRef

16.

Khan W, Augustine D, Rao RS, Patil S, Awan KH, Sowmya SV, Haragannavar VC, Prasad K (2021) Lipid metabolism in cancer: a systematic review. J Carcinog 20:4. https://doi.org/10.4103/jcar.JCar_15_20CrossRef

17.

Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610–2623. https://doi.org/10.1111/j.1742-4658.2012.08644.xCrossRef

18.

Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC, Dittmer DP, Damania B (2012) Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Natl Acad Sci U S A 109(29):11818–11823. https://doi.org/10.1073/pnas.1205995109CrossRef

19.

Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreundschuh M, Trümper L, Loeffler M et al (2015) Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 29(7):1564–1570. https://doi.org/10.1038/leu.2015.43CrossRef

20.

Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N, Sedivy JM, Zeller KI, Dang CV (2008) Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 3(7):e2722. https://doi.org/10.1371/journal.pone.0002722CrossRef

21.

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762–765. https://doi.org/10.1038/nature07823CrossRef

22.

Broecker-Preuss M, Becher-Boveleth N, Bockisch A, Dührsen U, Müller S (2017) Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability. J Transl Med 15(1):158. https://doi.org/10.1186/s12967-017-1258-9CrossRef

23.

Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN (2014) Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc Natl Acad Sci U S A 111(29):10450–10455. https://doi.org/10.1073/pnas.1409778111CrossRef

24.

Singh A, Nandwana V, Rink JS, Ryoo SR, Chen TH, Allen SD, Scott EA, Gordon LI, Thaxton CS, Dravid VP (2019) Biomimetic magnetic nanostructures: a theranostic platform targeting lipid metabolism and immune response in lymphoma. ACS Nano 13(9):10301–10311. https://doi.org/10.1021/acsnano.9b03727CrossRef

25.

Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J (1987) Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 257(7):943–948CrossRef

26.

Kim J, Kim MK, Baek KH, Song KH, Han K, Kwon HS (2022) Repeated low high-density lipoprotein cholesterol and the risk of thyroid cancer: a nationwide population- based study in Korea. Endocrinol Metab (Seoul) 37(2):303–311. https://doi.org/10.3803/EnM.2021.1332CrossRef

27.

van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A, Overvad K, Toft-Petersen AP, Tjonneland A, Hansen L, Boutron-Ruault MC, Clavel-Chapelon F, Cottet V, Palli D, Tagliabue G, Panico S, Tumino R et al (2011) Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 60(8):1094–1102. https://doi.org/10.1136/gut.2010.225011CrossRef

28.

Zhou P, Li B, Liu B, Chen T, Xiao J (2018) Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: a systematic review and meta-analysis. Clin Chim Acta 477:94–104. https://doi.org/10.1016/j.cca.2017.11.039CrossRef

29.

Chang H, Wei JW, Chen K, Zhang S, Han F, Lu LX, Xiao WW, Gao YH (2018) Apolipoprotein A-I is a prognosticator of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. J Cancer 9(4):702–710. https://doi.org/10.7150/jca.22836CrossRef

30.

Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B (2017) Impact of serum apolipoprotein A-I on prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer: a propensity score-matched analysis. Transl Oncol 10(2):288–294. https://doi.org/10.1016/j.tranon.2017.01.006CrossRef

31.

Pakzad R, Safiri S (2017) The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer: methodological issue. Breast 36:103–104. https://doi.org/10.1016/j.breast.2017.01.014CrossRef

32.

Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK (1982) Plasma lipid alterations in leukemia and lymphoma. Am J Med 72(5):775–782. https://doi.org/10.1016/0002-9343(82)90543-5CrossRef

33.

Matsuo T, Tashiro H, Shirasaki R, Sumiyoshi R, Yamamoto T, Saito S, Matsumoto K, Ooi J, Shirafuji N (2022) Serum high-density lipoprotein cholesterol level has a significant prognostic impact on outcomes of follicular lymphoma patients. Medicine (Baltimore) 101(30):e29541. https://doi.org/10.1097/MD.0000000000029541CrossRef

34.

Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J, Johnson CC (2018) Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer causes & control : CCC 29(1):143–156. https://doi.org/10.1007/s10552-017-0987-7CrossRef

35.

Ikonen E (2008) Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9(2):125–138. https://doi.org/10.1038/nrm2336CrossRef

36.

Strasak AM, Pfeiffer RM, Brant LJ, Rapp K, Hilbe W, Oberaigner W, Lang S, Borena W, Concin H, Diem G, Ruttmann E, Glodny B, Pfeiffer KP, Ulmer H (2009) Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol 20(6):1113–1120. https://doi.org/10.1093/annonc/mdn736CrossRef

37.

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ (2014) Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 23(11):2349–2356. https://doi.org/10.1158/1055-9965.Epi-14-0458CrossRef

38.

Cardwell CR, Hicks BM, Hughes C, Murray LJ (2014) Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 32(28):3177–3183. https://doi.org/10.1200/jco.2013.54.4569CrossRef

39.

Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802. https://doi.org/10.1056/NEJMoa1201735CrossRef

40.

Pernes G, Flynn MC, Lancaster GI, Murphy AJ (2019) Fat for fuel: lipid metabolism in haematopoiesis. Clin Transl Immunology 8(12):e1098. https://doi.org/10.1002/cti2.1098CrossRef

41.

Kuliszkiewicz-Janus M, Małecki R, Mohamed AS (2008) Lipid changes occuring in the course of hematological cancers. Cell Mol Biol Lett 13(3):465–474. https://doi.org/10.2478/s11658-008-0014-9CrossRef

42.

Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, Jonsson H, Bjørge T, Manjer J, Häggström C, Engeland A, Ulmer H, Selmer R, Concin H, Stattin P, Schlenk RF (2012) Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol 91(10):1519–1531. https://doi.org/10.1007/s00277-012-1489-zCrossRef

43.

Jeong SM, Choi T, Kim D, Han K, Kim SJ, Rhee SY, Giovannucci EL, Shin DW (2021) Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia 35(5):1356–1364. https://doi.org/10.1038/s41375-020-01081-5CrossRef

44.

Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Albanes D (2007) Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Res 67(11):5569–5574. https://doi.org/10.1158/0008-5472.Can-07-0212CrossRef

45.

Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, Uchida K, O'Connor OA, Stockwell BR (2019) Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol 26(5):623–633.e629. https://doi.org/10.1016/j.chembiol.2019.01.008CrossRef

46.

Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, Nitta E, Shigenaga J, Schnell Heringer A, Ganz P, Graf J (2014) Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 3(5):e001267. https://doi.org/10.1161/JAHA.114.001267CrossRef

47.

Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18(2):153–161. https://doi.org/10.1016/j.cmet.2013.05.017CrossRef

48.

Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA (2013) SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23(6):826–838. https://doi.org/10.1016/j.ccr.2013.05.002CrossRef

49.

Benakanakere I, Johnson T, Sleightholm R, Villeda V, Arya M, Bobba R, Freter C, Huang C (2014) Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells. Exp Hematol Oncol 3:24. https://doi.org/10.1186/2162-3619-3-24CrossRef

50.

Unruh TL, Li H, Mutch CM, Shariat N, Grigoriou L, Sanyal R, Brown CB, Deans JP (2005) Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 116(2):223–232. https://doi.org/10.1111/j.1365-2567.2005.02213.xCrossRef

51.

Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW et al (2008) Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5(3):e64. https://doi.org/10.1371/journal.pmed.0050064CrossRef

Titel: Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab
verfasst von: Fei Wang
Luo Lu
HuiJuan Chen
Yanhua Yue
Yanting Sun
Feng Yan
Bai He
Rongrong Lin
Weiying Gu
Publikationsdatum: 21.01.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2023
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05092-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Correction to: A real‑world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia

Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia

Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation

Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin